Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

INTRODUCTION: Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Surg Oncol
Glavni autori: Bello, Danielle M., Panageas, Katherine S., Hollmann, Travis, Shoushtari, Alexander N., Momtaz, Parisa, Chapman, Paul B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Brady, Mary S., Coit, Daniel G., Ariyan, Charlotte E.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7112166/
https://ncbi.nlm.nih.gov/pubmed/31848819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08099-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items